PORTFOLIO MANAGER Q&A | AS OF OCTOBER 31, 2023

Fidelity® International Growth Fund

Key Takeaways

- For the fiscal year ending October 31, 2023, the fund's Retail Class shares gained 10.59%, versus 10.95% for the benchmark MSCI EAFE Growth Index.
- International stocks generated a double-digit gain the past 12 months, with interest rates and inflation being top of mind among investors, according to Portfolio Manager Jed Weiss. The early-March U.S. regional banking crisis, which bled into other areas of the globe to an extent, was another focal point.
- Sector-wise, picks among information technology and industrials stocks detracted most from performance compared with the benchmark. Geographically, security selection and a sizable underweight in Japan proved most detrimental, followed by investment choices in Switzerland and Germany.
- On a stock-specific basis, the largest relative detractors included U.S.-based sleep apnea device maker ResMed (-37%), Danish drugmaker Novo Nordisk (+37%), as well as Japanese factory automation companies Misumi (-30%) and Keyence (+2%).
- In contrast, from a sector standpoint, stock picks in materials and financials – especially financial services firms – contributed most this period. A noteworthy underweight among health care companies also proved beneficial. On a country basis, security selection in Ireland, Sweden and the U.K. stood out to the upside, as did a considerable underweight in Swiss equity markets.
- Turning to individual holdings, Irish building materials firm CRH (+52%) and France-based aircraft engine and aerospace systems company Safran (+41%) bolstered the portfolio's relative return.
- As of October 31, Jed feels that the magnitude of interest rate hikes economies experienced over the past 12 to 18 months is not likely to repeat over a comparable near-term time horizon.

MARKET RECAP

International (non-U.S.) equities gained 12.27% for the 12 months ending October 31, 2023, according to the MSCI ACWI (All Country World Index) ex USA Index, as global economic expansion and slowing inflation in some markets provided a favorable backdrop for risk assets. After returning -15.86% in 2022, the index's upturn has been largely driven by a narrow set of companies in the information technology and communication services sectors, in part due to excitement about generative artificial intelligence. The index rose 14.07% year to date through July, including gains in both June (+4.50%) and July (+4.07%). The rally sputtered for the next three months (-11.33%), however, amid a stalling pattern in disinflationary trends, heightened global recession and geopolitical risks, soaring yields on long-term U.S. government bonds and weak economic conditions in the eurozone as well as China. The three-month decline left non-U.S. stocks up 1.15% year to date through October. Currency fluctuation also helped bolster non-U.S. equity performance overall. For the full 12 months, nearly all regions advanced, with Europe ex U.K. (+18%) and Japan (+17%) leading, whereas Canada (-0.38%) lagged by the widest margin. Each of the 11 sectors advanced, with information technology (+21%) and consumer discretionary (+19%) leading the way. Conversely, four defensive-oriented sectors lagged by the widest margin: real estate (+4%), health care (+6%), consumer staples (+7%) and utilities (+8%).

Jed Weiss
Portfolio Manager

Fund Facts

Trading Symbol:	FIGFX
Start Date:	November 01, 2007
Size (in millions):	$4,343.81

Investment Approach

- Fidelity® International Growth Fund is a diversified international equity strategy with a large-cap growth orientation.
- Our investment approach targets companies with multiyear structural growth prospects, high barriers to entry and attractive valuations based on our earnings forecasts.
- Investment ideas typically fall into three main categories: structurally attractive growth themes, where investors may be underestimating the durability of growth drivers and long-term earnings power; cyclically out-of-favor companies with limited competition and pricing power, where investors may be focusing on near-term cyclical concerns and discounting long-term prospects; and companies with strong earnings potential whose share prices have fallen due to macroeconomic events.
- We strive to uncover these companies through in-depth fundamental analysis, working in concert with Fidelity's global research team, with the goal of capturing market upside while limiting downside participation.

Q&A

An interview with Portfolio Manager Jed Weiss

Q: Jed, how did the fund perform for the fiscal year ending October 31, 2023?

The fund's Retail Class shares gained 10.59% the past 12 months, versus 10.95% for the benchmark MSCI EAFE Growth Index and 9.08% for the peer group average.

As a reminder to shareholders, my investment approach targets companies with multiyear structural-growth prospects, high barriers to entry and attractive valuations, based on my earnings forecasts. Consequently, compared with the benchmark, the portfolio's positioning – in terms of sectors, regions and countries – is predominantly a function of where I find stock-specific opportunities.

Q: What was noteworthy about international equity markets during the period?

Overseas stocks generated a double-digit gain the past 12 months, with interest rates and inflation being top of mind among investors. The period followed a significant market downturn as the U.S. Federal Reserve was aggressively raising interest rates to combat elevated inflation. Then, equities began to rally in the final few months of 2022 and early 2023 as market participants became optimistic that inflation was rolling over and the Fed, along with several other key central banks around the world, may be nearing the end of their rate-hike campaigns. That said, inflation has proven more durable than investors would have hoped.

Another noteworthy event impacting international stock markets was the early-March U.S. regional banking crisis, which bled into other areas of the globe to an extent. Specifically, financial institutions in Europe also came under close scrutiny, with Credit Suisse – Switzerland's second-largest bank – collapsing amid a series of scandals, management changes and significant losses. To help stabilize the global financial system, it was purchased at a distressed price and with government guarantees by rival UBS Group.

Q: Against this backdrop, what detracted most from performance versus the benchmark?

Sector-wise, picks among information technology and industrials stocks pressured performance most compared with the benchmark. Geographically, security selection and a sizable underweight in Japan proved detrimental.

Investment choices in Switzerland and Germany also hurt.

From a stock-specific standpoint, the portfolio's largest relative detractor was an out-of-benchmark position in U.S.-based ResMed (-37%). The company is the market leader in sleep apnea devices and masks, with considerable market share in this underpenetrated industry. Essentially, two things went wrong this period that caused the stock to underperform. First, it's number one competitor, Philips Respironics, was temporarily forced out of the market due to several issues with its devices, leading to recalls by the U.S. Food and Drug Administration. Despite this favorable competitive tailwind, ResMed has been unable to capitalize on this single-player market opportunity. Instead, the firm has been coming up short of earnings expectations because of profit-margin pressure stemming from high inflation, which it has not yet been able to pass on to customers through higher prices. Another key factor weighing on the business is the potential negative impact of popular GLP-1 injectable weight-loss drugs (Ozempic®, Wegovy®, Trulicity®, etc.), initially used to treat diabetes. Given the link between obesity and sleep apnea, the thought is that more widespread use of these treatments could lead to less reliance on continuous positive airway pressure machines. While actual evidence to support this may only come to light in due time, the potential long-term threat to the sleep apnea market has weighed on valuations of firms within the industry in the near term. Although we continue to own the stock, I did reduce exposure to it somewhat these past 12 months.

Untimely positioning in Danish drugmaker Novo Nordisk also hurt the portfolio's relative return, given the stock's 79% gain within the benchmark, versus 37% in the fund. Despite many years of prior ownership, I entered the period with no exposure to the stock. Having said that, I concluded the reporting period with an overweight, as my conviction in the company grew. One catalyst was an early-August study showing that, in addition to weight loss, Wegovy®– the firm's GLP-1 treatment – provided notable cardiovascular benefits, including a reduced risk of heart attack. These results caused shares of the firm to surge markedly higher. More important, it represents a significant finding that I am hopeful could lead to increased coverage by insurance providers, based on the drug's potential health advantages beyond weight loss alone. Though it was a moderate overweight, Novo Nordisk was the portfolio's second-largest holding at the end of the reporting period.

Elsewhere in the fund, outsized stakes in a Japanese factory automation companies Misumi (-30%) and Keyence (+2%) were hindered by apprehension over a global macroeconomic and cyclical slowdown. This was especially concerning as it related to China, where many Japan-based exporters have meaningful exposure. Nonetheless, I modestly added to Keyence this period, a top-10 holding as of October 31.

Q: Shifting gears, what aided performance?

From a sector standpoint, stock picks in materials and financials – especially financial services firms – led the way. A noteworthy underweight among health care companies also proved beneficial. On a country basis, security selection in Ireland, Sweden and the U.K. stood out to the upside, as did a considerable underweight in Swiss equity markets.

Turning to individual holdings, a non-benchmark position in Irish building materials firm CRH (+52%) topped the list of relative contributors these past 12 months. This vertically integrated business manufactures and supplies a variety of construction products, including aggregates and cement, in addition to having a solid history of making opportunistic acquisitions and expanding its profit margin. Furthermore, shares of CRH appear to be well-positioned in the U.S. to take advantage of investor optimism for both infrastructure programs and broader cyclical tailwinds as the Fed seemingly winds down its policy tightening efforts, providing a possible catalyst to reaccelerate growth.

Lastly, overweight exposure to France-based narrow-body aircraft engine and aerospace systems company Safran (+41%) added value compared with the benchmark. From a competitive point of view, the firm has a joint venture with General Electric to represent one half of a duopoly, whereas Germany's MTU Aero Engines partners with U.S.-headquartered United Technologies to make up the other half. Safran was well-positioned during the COVID-19 pandemic in that it was able to significantly cut costs within its European manufacturing base in ways that simply would not have been possible under normal circumstances. This enabled the business to emerge from the pandemic with a strong balance sheet in an industry that has benefited from a recovery in travel, all while its chief rival is suffering from considerable performance issues, leading to increased market share and better engine pricing. As such, I added to the stock a bit the past 12 months, making it a top-10 holding as of period end.

Q: Any final thoughts for shareholders, Jed?

As of October 31, monetary policy by the Fed continues to be a major focal point among market participants, and while I wouldn't pretend to know exactly what the future holds in this regard, I don't think that the magnitude of rate hikes we experienced over the past 12 to 18 months is likely to repeat over a comparable near-term time horizon. As always, however, regardless of the prevailing market backdrop, I plan to stick to my investment approach to target companies with multiyear structural-growth prospects, high barriers to entry and attractive valuations based on my earnings forecasts. ■

Jed Weiss on artificial intelligence – not just a U.S. story:

"There's no question that AI has dominated headlines in 2023, largely focused on several U.S.-domiciled stocks. Technology knows no geographic boundaries, though, and international equity markets offer many other ways to invest in this theme, often at substantially more attractive valuations in comparison to their U.S. counterparts.

"Domestic companies Nvidia and Microsoft have certainly done their parts to drive this technology forward. When thinking about hardware as it relates to AI, Nvidia clearly stands out and for good reason. But it's worth noting there are many downstream businesses that contribute to Nvidia's success. For example, it relies on the manufacturing capabilities of Taiwan Semiconductor Manufacturing, or TSMC, the semiconductor industry's dominant, leading-edge chipmaking foundry.

"In turn, TSMC itself leverages highly advanced tools, including extreme ultraviolet lithography, also known as EUV, to produce ever faster and smaller chips. Taking this a step further in terms of hardware, EUV would not be possible without the expertise of companies like ASML, the monopoly maker of EUV lithography machines, as well as Japan's Lasertec, the dominant supplier of inspection systems for EUV masks and mask blanks. Meanwhile, Dutch industrial manufacturing company Aalberts and Sweden's industrial automation equipment provider Atlas Copco are beneficiaries of the AI-powered structural growth in EUV and semiconductor technology as well.

"As it relates to software, the U.K.'s Sage Group utilizes AI and machine learning to drive faster and more efficient enterprise resource planning – namely integrated accounting, payroll and payment systems – the cornerstone of its offerings. In addition, U.S.-based Nice relies on AI to provide mission critical software and cloud routing capabilities for call centers.

"TSMC, ASML, Lasertec, Aalberts, Atlas Copco, Sage Group and Nice were all fund holdings as of October 31."

LARGEST CONTRIBUTORS VS. BENCHMARK

Holding	Market Segment	Average Relative Weight	Relative Contribution (basis points)*
CRH PLC sponsored ADR	Materials	2.00%	70
Safran SA	Industrials	2.23%	63
Linde PLC	Materials	2.51%	62
CSL Ltd.	Health Care	-1.22%	38
Taiwan Semiconductor Manufacturing Co. Ltd.	Information Technology	1.77%	35

** 1 basis point = 0.01%.*

LARGEST DETRACTORS VS. BENCHMARK

Holding	Market Segment	Average Relative Weight	Relative Contribution (basis points)*
ResMed, Inc.	Health Care	1.77%	-102
Misumi Group, Inc.	Industrials	1.05%	-50
Novo Nordisk A/S Series B sponsored ADR	Health Care	-1.03%	-35
Recruit Holdings Co. Ltd.	Industrials	1.12%	-34
SAP SE	Information Technology	-1.11%	-33

** 1 basis point = 0.01%.*

ASSET ALLOCATION

Asset Class	Portfolio Weight	Index Weight	Relative Weight	Relative Change From Six Months Ago
International Equities	81.29%	100.00%	-18.71%	3.66%
Developed Markets	76.60%	100.00%	-23.40%	3.12%
Emerging Markets	4.69%	0.00%	4.69%	0.54%
Tax-Advantaged Domiciles	0.00%	0.00%	0.00%	0.00%
Domestic Equities	16.68%	0.00%	16.68%	-2.92%
Bonds	0.00%	0.00%	0.00%	0.00%
Cash & Net Other Assets	2.03%	0.00%	2.03%	-0.74%

Net Other Assets can include fund receivables, fund payables, and offsets to other derivative positions, as well as certain assets that do not fall into any of the portfolio composition categories. Depending on the extent to which the fund invests in derivatives and the number of positions that are held for future settlement, Net Other Assets can be a negative number.

"Tax-Advantaged Domiciles" represent countries whose tax policies may be favorable for company incorporation.

MARKET-SEGMENT DIVERSIFICATION

Market Segment	Portfolio Weight	Index Weight	Relative Weight	Relative Change From Six Months Ago
Industrials	26.21%	18.80%	7.41%	-1.07%
Financials	17.90%	8.82%	9.08%	0.96%
Information Technology	16.59%	14.31%	2.28%	-1.19%
Consumer Discretionary	12.89%	15.18%	-2.29%	0.14%
Materials	8.80%	5.41%	3.39%	0.86%
Health Care	8.69%	17.81%	-9.12%	0.32%
Consumer Staples	4.92%	13.86%	-8.94%	0.74%
Energy	1.00%	0.33%	0.67%	0.22%
Communication Services	0.96%	3.89%	-2.93%	-0.07%
Utilities	0.00%	0.76%	-0.76%	-0.07%
Real Estate	0.00%	0.82%	-0.82%	-0.08%
Other	0.00%	0.00%	0.00%	0.00%

COUNTRY DIVERSIFICATION

Country	Portfolio Weight	Index Weight	Relative Weight	Relative Change From Six Months Ago
United States	16.68%	--	16.68%	-2.92%
France	14.67%	14.25%	0.42%	0.98%
Japan	10.46%	21.58%	-11.12%	-1.69%
United Kingdom	8.58%	10.05%	-1.47%	2.07%
Switzerland	7.10%	12.71%	-5.61%	0.58%
Ireland	6.42%	0.80%	5.62%	4.54%
Netherlands	6.10%	6.57%	-0.47%	-0.71%
Denmark	5.75%	6.48%	-0.73%	1.02%
Sweden	5.59%	3.15%	2.44%	-0.09%
Canada	3.49%	--	3.49%	0.22%
Taiwan	2.17%	--	2.17%	0.45%
India	2.13%	--	2.13%	0.39%
Spain	1.91%	1.50%	0.41%	-0.49%
Hong Kong	1.76%	2.59%	-0.83%	-0.58%
Italy	1.33%	1.32%	0.01%	-0.05%
Germany	1.18%	7.30%	-6.12%	-1.65%
Other Countries	2.57%	N/A	N/A	N/A
Cash & Net Other Assets	2.11%	0.00%	2.11%	-0.70%

10 LARGEST HOLDINGS

Holding	Market Segment	Portfolio Weight	Portfolio Weight Six Months Ago
ASML Holding NV (Netherlands)	Information Technology	5.31%	5.63%
Novo Nordisk A/S Series B	Health Care	5.21%	3.07%
LVMH Moet Hennessy Louis Vuitton SE	Consumer Discretionary	5.11%	6.19%
Nestle SA (Reg. S)	Consumer Staples	4.74%	4.90%
Linde PLC	Materials	4.08%	3.74%
Safran SA	Industrials	3.61%	2.92%
Keyence Corp.	Information Technology	3.14%	3.11%
Atlas Copco AB (A Shares)	Industrials	2.97%	2.87%
Marsh & McLennan Companies, Inc.	Financials	2.83%	2.73%
Airbus Group NV	Industrials	2.78%	2.51%
10 Largest Holdings as a % of Net Assets		**39.78%**	**37.77%**
Total Number of Holdings		**75**	**76**

The 10 largest holdings are as of the end of the reporting period, and may not be representative of the fund's current or future investments. Holdings do not include money market investments.

FISCAL PERFORMANCE SUMMARY: Periods ending October 31, 2023

	Cumulative		Annualized			
	6 Month	YTD	1 Year	3 Year	5 Year	10 Year/ LOF[1]
Fidelity International Growth Fund Gross Expense Ratio: 1.01%[2]	-8.29%	2.89%	10.59%	1.61%	6.62%	5.22%
MSCI EAFE Growth Index (Net MA)	-11.67%	0.59%	10.95%	0.61%	4.62%	3.92%
Morningstar Fund Foreign Large Growth	-9.94%	-0.01%	9.08%	-1.89%	4.18%	3.75%
% Rank in Morningstar Category (1% = Best)	--	--	45%	23%	17%	19%
# of Funds in Morningstar Category	--	--	414	383	332	229

[1] Life of Fund (LOF) if performance is less than 10 years. Fund inception date: 11/01/2007.

[2] This expense ratio is from the prospectus in effect as of the date shown above and generally is based on amounts incurred during that fiscal year, or estimated amounts for the current fiscal year in the case of a newly launched fund. It does not include any fee waivers or reimbursements, which would be reflected in the fund's net expense ratio.

Past performance is no guarantee of future results. Investment return and principal value of an investment will fluctuate; therefore, you may have a gain or loss when you sell your shares. Current performance may be higher or lower than the performance stated. Performance shown is that of the fund's Retail Class shares (if multiclass). You may own another share class of the fund with a different expense structure and, thus, have different returns. To learn more or to obtain the most recent month-end or other share-class performance, visit fidelity.com/performance, institutional. fidelity.com, or 401k.com. Total returns are historical and include change in share value and reinvestment of dividends and capital gains, if any. Cumulative total returns are reported as of the period indicated. **Please see the last page(s) of this Q&A document for most-recent calendar-quarter performance.**

Definitions and Important Information

Information provided in, and presentation of, this document are for informational and educational purposes only and are not a recommendation to take any particular action, or any action at all, nor an offer or solicitation to buy or sell any securities or services presented. It is not investment advice. Fidelity does not provide legal or tax advice.

Before making any investment decisions, you should consult with your own professional advisers and take into account all of the particular facts and circumstances of your individual situation. Fidelity and its representatives may have a conflict of interest in the products or services mentioned in these materials because they have a financial interest in them, and receive compensation, directly or indirectly, in connection with the management, distribution, and/or servicing of these products or services, including Fidelity funds, certain third-party funds and products, and certain investment services.

FUND RISKS

Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks, all of which are magnified in emerging markets.

IMPORTANT FUND INFORMATION

Relative positioning data presented in this commentary is based on the fund's primary benchmark (index) unless a secondary benchmark is provided to assess performance.

INDICES

It is not possible to invest directly in an index. All indices represented are unmanaged. All indices include reinvestment of dividends and interest income unless otherwise noted.

MSCI EAFE Growth Index (Net MA Tax) is a market-capitalization-weighted index that is designed to measure the investable equity market performance of growth stocks for global investors in developed markets, excluding the U.S. & Canada. Index returns are adjusted for tax withholding rates applicable to U.S. based mutual funds organized as Massachusetts business trusts.

MSCI ACWI (All Country World Index) ex USA Index is a market-capitalization-weighted index designed to measure the investable equity market performance for global investors of large and mid-cap stocks in developed and emerging markets, excluding the United States.

MARKET-SEGMENT WEIGHTS

Market-segment weights illustrate examples of sectors or industries in which the fund may invest, and may not be representative of the fund's current or future investments. They should not be construed or used as a recommendation for any sector or industry.

RANKING INFORMATION

 Fidelity does not review the Morningstar data and, for mutual fund performance, you should check the fund's current prospectus for the most up-to-date information concerning applicable loads, fees and expenses.

% Rank in Morningstar Category is the fund's total-return percentile rank relative to all funds that have the same Morningstar Category. The highest (or most favorable) percentile rank is 1 and the lowest (or least favorable) percentile rank is 100. The top-performing fund in a category will always receive a rank of 1%. % Rank in Morningstar Category is based on total returns which include reinvested dividends and capital gains, if any, and exclude sales charges. Multiple share classes of a fund have a common portfolio but impose different expense structures.

RELATIVE WEIGHTS

Relative weights represents the % of fund assets in a particular market segment, asset class or credit quality relative to the benchmark. A positive number represents an overweight, and a negative number is an underweight. The fund's benchmark is listed immediately under the fund name in the Performance Summary.

Manager Facts

Jed Weiss is a portfolio manager in the Equity division at Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing, and other financial products and services to institutions, financial intermediaries, and individuals.

In this role, Mr. Weiss manages Fidelity Series International Growth Fund, Fidelity Series International Small Cap Fund, Fidelity International Small Cap Opportunities Fund, Fidelity Advisor International Small Cap Opportunities Fund, Fidelity International Growth Fund, and Fidelity Advisor International Growth Fund. Additionally, he co-manages Fidelity Total International Equity Fund and Fidelity Advisor Total International Equity Fund.

Prior to assuming his current position in 2007, Mr. Weiss covered the telecommunications, health care, and consumer sectors as an analyst on Fidelity's Global Emerging Markets team. Previously, he worked as an analyst and portfolio manager of Select Environment Fund, during which he also covered a wide range of industries within the cyclical sector. Prior to that, Mr. Weiss held various other roles at Fidelity, including equity research analyst covering communications, semiconductors, and networking stocks, during which he also managed Select Networking and Infrastructure Portfolio. Additionally, he worked as an equity research analyst covering semiconductors and as an associate analyst covering U.S. regional banks.

Before joining Fidelity in 1997, Mr. Weiss was a summer associate at Goldman Sachs and a legislative affairs intern at the White House. He has been in the financial industry since 1997.

Mr. Weiss earned his bachelor of arts degree in government from Harvard University, where he graduated Phi Beta Kappa.

PERFORMANCE SUMMARY:
Quarter ending March 31, 2024

	Annualized			
	1 Year	3 Year	5 Year	10 Year/ LOF[1]
Fidelity International Growth Fund Gross Expense Ratio: 0.84%[2]	18.63%	4.93%	10.01%	7.46%
% Rank in Morningstar Category (1% = Best)	15%	11%	13%	16%
# of Funds in Morningstar Category	407	383	327	223

[1] Life of Fund (LOF) if performance is less than 10 years. Fund inception date: 11/01/2007.

[2] This expense ratio is from the prospectus in effect as of the date shown above and generally is based on amounts incurred during that fiscal year, or estimated amounts for the current fiscal year in the case of a newly launched fund. It does not include any fee waivers or reimbursements, which would be reflected in the fund's net expense ratio.

Past performance is no guarantee of future results. Investment return and principal value of an investment will fluctuate; therefore, you may have a gain or loss when you sell your shares. Current performance may be higher or lower than the performance stated. Performance shown is that of the fund's Retail Class shares (if multiclass). You may own another share class of the fund with a different expense structure and, thus, have different returns. To learn more or to obtain the most recent month-end or other share-class performance, visit fidelity.com/performance, institutional. fidelity.com, or 401k.com. Total returns are historical and include change in share value and reinvestment of dividends and capital gains, if any. Cumulative total returns are reported as of the period indicated.

Before investing in any mutual fund, please carefully consider the investment objectives, risks, charges, and expenses. For this and other information, call or write Fidelity for a free prospectus or, if available, a summary prospectus. Read it carefully before you invest.

Past performance is no guarantee of future results.

Views expressed are through the end of the period stated and do not necessarily represent the views of Fidelity. Views are subject to change at any time based upon market or other conditions and Fidelity disclaims any responsibility to update such views. These views may not be relied on as investment advice and, because investment decisions for a Fidelity fund are based on numerous factors, may not be relied on as an indication of trading intent on behalf of any Fidelity fund. The securities mentioned are not necessarily holdings invested in by the portfolio manager(s) or FMR LLC. References to specific company securities should not be construed as recommendations or investment advice.

Diversification does not ensure a profit or guarantee against a loss.

Information included on this page is as of the most recent calendar quarter.

Fidelity Brokerage Services LLC, Member NYSE, SIPC, 900 Salem Street, Smithfield, RI 02917.

Fidelity Distributors Company LLC, 500 Salem Street, Smithfield, RI 02917.

706818.19.0